1259 related articles for article (PubMed ID: 6548291)
1. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
2. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
3. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
5. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
7. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
Lee JH; el-Fakahany EE
J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
[TBL] [Abstract][Full Text] [Related]
9. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
10. Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
el-Fakahany EE; Ramkumar V; Lai WS
J Pharmacol Exp Ther; 1986 Aug; 238(2):554-63. PubMed ID: 3755473
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic receptors on rat isolated colonic epithelial cells. A correlation between inhibition of [3H]quinuclidinyl benzilate binding and alteration in ion transport.
Zimmerman TW; Binder HJ
Gastroenterology; 1982 Dec; 83(6):1244-51. PubMed ID: 6127277
[TBL] [Abstract][Full Text] [Related]
12. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
Ehlert FJ; Tran LP
J Pharmacol Exp Ther; 1990 Dec; 255(3):1148-57. PubMed ID: 2262898
[TBL] [Abstract][Full Text] [Related]
13. The binding of a 2-chloroethylamine derivative of oxotremorine (BM 123) to muscarinic receptors in the rat cerebral cortex.
Ehlert FJ; Jenden DJ
Mol Pharmacol; 1985 Aug; 28(2):107-19. PubMed ID: 3839562
[TBL] [Abstract][Full Text] [Related]
14. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
15. Light microscopic autoradiographic localization of [3H]pirenzepine and [3H](-)quinuclidinyl benzilate binding in human stellate ganglia.
Yamamura HI; Watson M; Wamsley JK; Johnson PC; Roeske WR
Life Sci; 1984 Aug; 35(7):753-7. PubMed ID: 6547993
[TBL] [Abstract][Full Text] [Related]
16. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study.
Tonnaer JA; Ernste BH; Wester J; Kelder K
J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343
[TBL] [Abstract][Full Text] [Related]
17. Evidence for muscarinic receptors on rat colonic epithelial cells: binding of [3H]quinuclidinyl benzilate.
Rimele TJ; O'Dorisio MS; Gaginella TS
J Pharmacol Exp Ther; 1981 Aug; 218(2):426-34. PubMed ID: 7252842
[TBL] [Abstract][Full Text] [Related]
18. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
19. [3H]tricyclopinate binding to brain muscarinic acetylcholine receptors: a comparison with [3H]quinuclidinyl benzilate.
Gao ZG; Liu CG
Pharmacol Res; 1996; 33(4-5):283-9. PubMed ID: 8938022
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological differences between the high-affinity muscarinic agonist binding states of the rat heart and cerebral cortex labeled with (+)-[3H]cismethyldioxolane.
Vickroy TW; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1984 Jun; 229(3):747-55. PubMed ID: 6202869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
